Radiation showdown: which schedule beats childhood brain cancer?
NCT ID NCT01351870
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This trial tested two different ways of giving radiation to children and teens with a standard-risk brain tumor called medulloblastoma. One group got standard daily radiation, while the other got smaller doses twice a day. The goal was to see which schedule better prevents the cancer from coming back. The study enrolled 52 participants aged 4 to 21.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Radiation therapy
What this could lead to
If successful, this could identify a more effective radiotherapy schedule for children with medulloblastoma, potentially improving disease control and survival.
What could go wrong
This is a completed Phase 3 trial with only 52 participants, so results may not apply broadly. Both regimens involve radiation, which carries risks of long-term side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEDULLOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut Curie
Paris, 75005, France